0000928816-19-000075.txt : 20190118 0000928816-19-000075.hdr.sgml : 20190118 20190118081847 ACCESSION NUMBER: 0000928816-19-000075 CONFORMED SUBMISSION TYPE: 485BPOS PUBLIC DOCUMENT COUNT: 13 FILED AS OF DATE: 20190118 DATE AS OF CHANGE: 20190118 EFFECTIVENESS DATE: 20190118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1933 Act SEC FILE NUMBER: 002-75863 FILM NUMBER: 19532184 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1940 Act SEC FILE NUMBER: 811-03386 FILM NUMBER: 19532183 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 0000357295 S000005666 PUTNAM GLOBAL HEALTH CARE FUND C000015515 Class A Shares PHSTX C000015516 Class B Shares PHSBX C000015517 Class C Shares PCHSX C000015518 Class M Shares PHLMX C000015519 Class R Shares PHSRX C000015520 Class Y Shares PHSYX 485BPOS 1 a_ghccover.htm PUTNAM GLOBAL HEALTH CARE FUND a_ghccvr.htm
As filed with the Securities and Exchange Commission on  
January 18, 2019  
 
Registration No. 811-03386 
2-75863 
----------------------------------------------------------------   
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
----------------  
FORM N-1A  
  ---- 
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  / X /
  ---- 
  ---- 
Pre-Effective Amendment No.  /    / 
  ---- 
  ---- 
Post-Effective Amendment No. 48  / X / 
and  ---- 
  ---- 
REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY  / X / 
ACT OF 1940  ---- 
---- 
Amendment No. 49  / X / 
(Check appropriate box or boxes)  ---- 
 
---------------  
PUTNAM GLOBAL HEALTH CARE FUND  
(Exact name of registrant as specified in charter)  
 
100 Federal Street, Boston, Massachusetts 02110  
(Address of principal executive offices)  
 
Registrant's Telephone Number, including Area Code  
(617) 292-1000  
----------------  

 



  It is proposed that this filing will become effective 
  (check appropriate box) 
----   
/    /  immediately upon filing pursuant to paragraph (b) 
----   
----   
/ X /  on December 30, 2018 pursuant to paragraph (b) 
----   
----   
/    /  60 days after filing pursuant to paragraph (a) (1) 
----   
----   
/    /  on (date) pursuant to paragraph (a) (1) 
----   
----   
/    /  75 days after filing pursuant to paragraph (a) (2) 
----   
----   
/    /  on (date) pursuant to paragraph (a) (2) of Rule 485. 
----   
 
If appropriate, check the following box: 
----   
/    /  this post-effective amendment designates a new 
----  effective date for a previously filed post-effective amendment. 
 
  -------------- 
 
  ROBERT T. BURNS, Vice President 
  PUTNAM GLOBAL HEALTH CARE FUND 
  100 Federal Street 
  Boston, Massachusetts 02110
  (Name and address of agent for service) 
  --------------- 
  Copy to: 
  BRYAN CHEGWIDDEN, Esquire 
  ROPES & GRAY LLP 
  1211 Avenue of the Americas 
  New York, New York 10036 

 




SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, and the Investment Company Act of 1940, as amended, the Registrant certifies that it meets all of the requirements for effectiveness of this Registration Statement under Rule 485(b) under the Securities Act of 1933, as amended, and has duly caused this Amendment to its Registration Statement to be signed on its behalf by the undersigned, duly authorized, in the City of Boston, and The Commonwealth of Massachusetts, on the 18th day of January, 2019.

 

 

PUTNAM GLOBAL HEALTH CARE FUND

 

By: /s/ Jonathan S. Horwitz, Executive Vice President, Principal Executive Officer and Compliance Liaison

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment to the Registration Statement has been signed below by the following persons in the capacities and on the date indicated:

 

Signature Title

 

Kenneth R. Leibler* Chair, Board of Trustees

 

Robert L. Reynolds* President and Trustee

 

Jonathan S. Horwitz* Executive Vice President, Principal Executive Officer and Compliance Liaison

 

Janet C. Smith* Vice President, Principal Financial Officer, Principal Accounting Officer and Assistant Treasurer

 

Liaquat Ahamed* Trustee

 

Ravi Akhoury* Trustee

 

Barbara M. Baumann* Trustee

 

Katinka Domotorffy* Trustee

 

Catherine Bond Hill* Trustee

 

Paul L. Joskow* Trustee

 

Robert E. Patterson* Trustee

 

George Putnam, III* Trustee

 

Manoj P. Singh* Trustee

 

 

 

By: /s/ Jonathan S. Horwitz, as Attorney-in-Fact January 18, 2019
  
*Signed pursuant to power of attorney filed in Post-Effective Amendment No. 47 to the Registrant's Registration Statement on December 27, 2018.

 

EX-101.INS 2 phstx-20181227.xml XBRL INSTANCE FILE 0000357295 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015516Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015517Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015518Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015519Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015520Member 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member rr:AfterTaxesOnDistributionsMember 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member rr:AfterTaxesOnDistributionsAndSalesMember 2018-12-27 2018-12-27 0000357295 PHSTX:S000005666Member PHSTX:MSCIWorldHealthCareIndexMember 2018-12-27 2018-12-27 iso4217:USD xbrli:pure 485BPOS 2017-12-31 PUTNAM GLOBAL HEALTH CARE FUND 0000357295 false PHSTX 2018-12-27 2018-12-30 2018-12-30 Fund Summary Goal Fees and expenses Shareholder fees (fees paid directly from your investment) Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment) Portfolio turnover Example Investments, risks, and performance Investments Risks It is important to understand that you can lose money by investing in the fund. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. Performance The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#8217;s performance year to year and over time. putnam.com Please remember that past performance is not necessarily an indication of future results. Annual total returns for class A shares before sales charges The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Year-to-date performance<br /><b>through 9/30/18</b>&#160;&#160;&#160;&#160;10.88%<br /><br />Best calendar quarter<br /><b>Q1 2013&#160;&#160;&#160;</b>13.14%<br /><br />Worst calendar quarter<br /><b>Q3 2011</b> &#160;&#160;&#160;&#160;&#8722;17.98% Best calendar quarter Worst calendar quarter Average annual total returns after sales charges (for periods ended 12/31/17) After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor's tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. Putnam Global Health Care Fund seeks capital appreciation. The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in <i>How do I buy fund shares? </i>beginning on page 50 of the fund's prospectus, in the Appendix to the fund's prospectus, and in <i>How to buy shares </i>beginning on page II-1 of the fund's statement of additional information (SAI). You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 50 of the fund's prospectus, in the Appendix to the fund's prospectus, and in How to buy shares beginning on page II-1 of the fund's statement of additional information (SAI). 50000 0.0575 0 0 0.0350 0 0 0.0100 0.0500 0.0100 0 0 0 <div style="display: none">~ http://xbrl.sec.gov/rr/role/ShareholderFeesData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> 0.0062 0.0062 0.0062 0.0062 0.0062 0.0062 0.0025 0.0100 0.0100 0.0075 0.0050 0.0021 0.0021 0.0021 0.0021 0.0021 0.0021 0.0108 0.0183 0.0183 0.0158 0.0133 0.0083 <div style="display: none">~ http://xbrl.sec.gov/rr/role/OperatingExpensesData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund&#8217;s operating expenses remain the same. Your actual costs may be higher or lower. 1816 1951 2148 2163 1601 1025 1136 1190 990 1180 729 460 899 876 576 831 421 265 679 686 286 505 135 85 1951 2148 990 990 576 576 186 186 <div style="display: none">~ http://xbrl.sec.gov/rr/role/ExpenseExample column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> <div style="display: none">~ http://xbrl.sec.gov/rr/role/ExpenseExampleNoRedemption column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or &#8220;turns over&#8221; its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund&#8217;s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund&#8217;s turnover rate in the most recent fiscal year was 49%. 0.49 Investments<br /> For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and<br /> midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund&#8217;s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days&#8217; notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company&#8217;s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.<br /> <br /> The use of the term &#8220;global&#8221; in the fund&#8217;s name is meant to emphasize that we look for investment opportunities on a worldwide basis and that our investment strategies are not constrained by the countries or regions in which companies are located. Under normal market conditions, the fund intends to invest in at least five different countries and at least 40% of its net assets in securities of foreign companies (or, if less, at least the percentage of net assets that is 10% less than the percentage of the fund&#8217;s benchmark represented by foreign companies, as determined by the providers of the benchmark).<br /> It is important to understand that you can lose money by investing in the fund.<br /> <br /> The value of stocks in the fund&#8217;s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in the financial markets, and factors related to a specific issuer or industry. These and other factors may lead to increased volatility and reduced liquidity in the fund&#8217;s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund&#8217;s &#8220;non-diversified&#8221; status, which means the fund may invest a greater percentage of its assets in fewer issuers than a &#8220;diversified fund,&#8221; can increase the fund&#8217;s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation), and may be illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value. <br /> <br /> The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. Our policy of concentrating on a limited group of industries and the fund's "non-diversified" status, which means the fund may invest a greater percentage of its assets in fewer issuers than a "diversified fund," can increase the fund's vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#8217;s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com. -0.1712 0.2517 0.0206 -0.0141 0.2198 0.4172 0.2747 0.0754 -0.1168 0.1528 Year-to-date performance through 2018-09-30 0.1088 2013-03-31 0.1314 2011-09-30 -0.1798 <div style="display: none">~ http://xbrl.sec.gov/rr/role/BarChartData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> 0.0903 0.0902 0.0885 0.0874 0.0940 0.0995 0.0688 0.0703 0.0894 0.1326 0.1356 0.1375 0.1324 0.1432 0.1490 0.1016 0.1025 0.1388 0.0865 0.0994 0.1346 0.1070 0.1495 0.1555 0.0483 0.0804 0.1980 <div style="display: none">~ http://xbrl.sec.gov/rr/role/PerformanceTableData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor&#8217;s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement. <br /><br /> Class B share performance reflects conversion to class A shares after eight years. before taxes before taxes before taxes before taxes before taxes before taxes Applies only to certain redemptions of shares bought with no initial sales charge. This charge is phased out over six years. This charge is eliminated after one year. EX-101.SCH 3 phstx-20181227.xsd XBRL SCHEMA FILE 00000003 - Document - Putnam Global Health Care Fund Summary {Unlabeled} link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 phstx-20181227_def.xml XBRL DEFINITION FILE EX-101.LAB 5 phstx-20181227_lab.xml XBRL LABEL FILE Legal Entity [Axis] Putnam Global Health Care Fund Legal Entity [Axis] Class A Class B Class C Class M Class R Class Y Performance Measure [Axis] after taxes on distributions after taxes on distributions and sale of fund shares MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes) Prospectus: [Table] Prospectus [Line Items] Risk/Return [Heading] Objective [Heading] Objective, Primary [Text Block] Objective, Secondary [Text Block] Expense [Heading] Expense Narrative [Text Block] Shareholder Fees Caption [Text] Shareholder Fees [Table] Operating Expenses Caption [Text] Annual Fund Operating Expenses [Table] Expense Footnotes [Text Block] Expenses Deferred Charges [Text Block] Expenses Range of Exchange Fees [Text Block] Expense Example [Heading] Expense Example by Year [Heading] Expense Example Narrative [Text Block] Expense Example by, Year, Caption [Text] Expense Example, With Redemption [Table] Expense Example, No Redemption Narrative [Text Block] Expense Example, No Redemption, By Year, Caption [Text] Expense Example, No Redemption [Table] Expense Example Footnotes [Text Block] Expense Example Closing [Text Block] Portfolio Turnover [Heading] Portfolio Turnover [Text Block] Strategy [Heading] Strategy Narrative [Text Block] Risk [Heading] Risk Narrative [Text Block] Risk Footnotes [Text Block] Risk Closing [Text Block] Bar Chart and Performance Table [Heading] Performance Narrative [Text Block] Bar Chart Narrative [Text Block] Bar Chart [Heading] Bar Chart [Table] Bar Chart Footnotes [Text Block] Bar Chart Closing [Text Block] Performance Table Heading Performance Table Narrative Performance [Table] Market Index Performance [Table] Performance Table Footnotes Performance Table Closing [Text Block] Shareholder Fees Column [Text] Maximum Cumulative Sales Charge (as a percentage of Offering Price) Maximum Cumulative Sales Charge (as a percentage) Maximum sales charge (load) imposed on purchases (as a percentage of offering price) Maximum Deferred Sales Charge (as a percentage of Offering Price) Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) Maximum Sales Charge on Reinvested Dividends and Distributions (as a percentage) Redemption Fee (as a percentage of Amount Redeemed) Redemption Fee Exchange Fee (as a percentage of Amount Redeemed) Exchange Fee Maximum Account Fee (as a percentage of Assets) Maximum Account Fee Shareholder Fee, Other Operating Expenses Column [Text] Management fees Distribution and service (12b-1) fees Distribution or Similar (Non 12b-1) Fees Component1 Other Expenses Component2 Other Expenses Component3 Other Expenses Other expenses Acquired fund fees and expenses Total annual fund operating expenses Fee Waiver or Reimbursement Net Expenses (as a percentage of Assets) Expense Example, By Year, Column [Text] Expense Example, with Redemption, 1 Year Expense Example, with Redemption, 3 Years Expense Example, with Redemption, 5 Years Expense Example, with Redemption, 10 Years Expense Example, No Redemption, By Year, Column [Text] Expense Example, No Redemption, 1 Year Expense Example, No Redemption, 3 Years Expense Example, No Redemption, 5 Years Expense Example, No Redemption, 10 Years Annual Return Caption [Text] Annual Return, Column [Text] Annual Return, Inception Date Annual Return 1990 Annual Return 1991 Annual Return 1992 Annual Return 1993 Annual Return 1994 Annual Return 1995 Annual Return 1996 Annual Return 1997 Annual Return 1998 Annual Return 1999 Annual Return 2000 Annual Return 2001 Annual Return 2002 Annual Return 2003 Annual Return 2004 Annual Return 2005 Annual Return 2006 Annual Return 2007 Annual Return 2008 Annual Return 2009 Annual Return 2010 Annual Return 2011 Annual Return 2012 Annual Return 2013 Annual Return 2014 Annual Return 2015 Annual Return 2016 Annual Return 2017 Annual Return 2018 Annual Return 2019 Annual Return 2020 Label 1 Year 5 Years 10 Years Since Inception Inception Date Risk/Return Detail [Table] Document Type Document Period End Date Registrant Name Central Index Key Amendment Flag Amendment Description Trading Symbol Document Creation Date Document Effective Date Prospectus Date Fee Waiver or Reimbursement over Assets, Date of Termination Portfolio Turnover, Rate Expense Breakpoint Discounts [Text] Expense Breakpoint, Minimum Investment Required [Amount] Expense Exchange Traded Fund Commissions [Text] Expenses Represent Both Master and Feeder [Text] Expenses Explanation of Nonrecurring Account Fee [Text] Other Expenses, New Fund, Based on Estimates [Text] Acquired Fund Fees and Expenses, Based on Estimates [Text] Expenses Other Expenses Had Extraordinary Expenses Been Included [Text] Expenses Restated to Reflect Current [Text] Expenses Not Correlated to Ratio Due to Acquired Fund Fees [Text] Strategy Portfolio Concentration [Text] Risk Lose Money [Text] Risk Nondiversified Status [Text] Risk Not Insured Depository Institution [Text] Risk Caption Risk Column [Text] Risk [Text] Performance Information Illustrates Variability of Returns [Text] Performance One Year or Less [Text] Performance Additional Market Index [Text] Performance Availability Phone [Text] Performance Availability Website Address [Text] Performance Past Does Not Indicate Future [Text] Bar Chart Does Not Reflect Sales Loads [Text] Bar Chart, Reason Selected Class Different from Immediately Preceding Period [Text] Bar Chart, Returns for Class Not Offered in Prospectus [Text] Year to Date Return, Label Bar Chart, Year to Date Return, Date Bar Chart, Year to Date Return Highest Quarterly Return, Label Highest Quarterly Return, Date Highest Quarterly Return Lowest Quarterly Return, Label Lowest Quarterly Return, Date Lowest Quarterly Return Performance Table Does Reflect Sales Loads Performance Table Market Index Changed Index No Deduction for Fees, Expenses, Taxes [Text] Performance Table Uses Highest Federal Rate Performance Table Not Relevant to Tax Deferred Performance Table One Class of after Tax Shown [Text] Performance Table Explanation after Tax Higher Performance Table Footnotes, Reason Performance Information for Class Different from Immediately Preceding Period [Text] Caption Column Money Market Seven Day Yield, Caption [Text] Money Market Seven Day Yield Column [Text] Money Market Seven Day Yield Phone Money Market Seven Day Yield Money Market Seven Day Tax Equivalent Yield Thirty Day Yield Caption Thirty Day Yield Column [Text] Thirty Day Yield Phone Thirty Day Yield Thirty Day Tax Equivalent Yield Share Class [Axis] EX-101.PRE 6 phstx-20181227_pre.xml XBRL PRESENTATION FILE GRAPHIC 8 BarChart1.png IDEA: XBRL DOCUMENT begin 644 BarChart1.png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htm IDEA: XBRL DOCUMENT v3.10.0.1
Putnam Global Health Care Fund
Fund Summary
Goal
Putnam Global Health Care Fund seeks capital appreciation.
Fees and expenses
The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 50 of the fund's prospectus, in the Appendix to the fund's prospectus, and in How to buy shares beginning on page II-1 of the fund's statement of additional information (SAI).
Shareholder fees (fees paid directly from your investment)
Shareholder Fees - Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) 5.75% none none 3.50% none none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) 1.00% [1] 5.00% [2] 1.00% [3] none none none
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] This charge is phased out over six years.
[3] This charge is eliminated after one year.
Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Annual Fund Operating Expenses - Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Management fees 0.62% 0.62% 0.62% 0.62% 0.62% 0.62%
Distribution and service (12b-1) fees 0.25% 1.00% 1.00% 0.75% 0.50%  
Other expenses 0.21% 0.21% 0.21% 0.21% 0.21% 0.21%
Total annual fund operating expenses 1.08% 1.83% 1.83% 1.58% 1.33% 0.83%
Example
The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Expense Example - Putnam Global Health Care Fund - USD ($)
Expense Example, with Redemption, 1 Year
Expense Example, with Redemption, 3 Years
Expense Example, with Redemption, 5 Years
Expense Example, with Redemption, 10 Years
Class A 679 899 1,136 1,816
Class B 686 876 1,190 1,951
Class C 286 576 990 2,148
Class M 505 831 1,180 2,163
Class R 135 421 729 1,601
Class Y 85 265 460 1,025
Expense Example, No Redemption - Putnam Global Health Care Fund - USD ($)
Expense Example, No Redemption, 1 Year
Expense Example, No Redemption, 3 Years
Expense Example, No Redemption, 5 Years
Expense Example, No Redemption, 10 Years
Class B 186 576 990 1,951
Class C 186 576 990 2,148
Portfolio turnover
The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 49%.
Investments, risks, and performance Investments
Investments
For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and
midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund’s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days’ notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.

The use of the term “global” in the fund’s name is meant to emphasize that we look for investment opportunities on a worldwide basis and that our investment strategies are not constrained by the countries or regions in which companies are located. Under normal market conditions, the fund intends to invest in at least five different countries and at least 40% of its net assets in securities of foreign companies (or, if less, at least the percentage of net assets that is 10% less than the percentage of the fund’s benchmark represented by foreign companies, as determined by the providers of the benchmark).
Risks
It is important to understand that you can lose money by investing in the fund.

The value of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in the financial markets, and factors related to a specific issuer or industry. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest a greater percentage of its assets in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation), and may be illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Performance
The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Annual total returns for class A shares before sales charges
Bar Chart
Year-to-date performance
through 9/30/18    10.88%

Best calendar quarter
Q1 2013   13.14%

Worst calendar quarter
Q3 2011     −17.98%
Average annual total returns after sales charges (for periods ended 12/31/17)
Average Annual Total Returns - Putnam Global Health Care Fund
Label
1 Year
5 Years
10 Years
Class A before taxes 8.65% 13.26% 9.03%
Class A | after taxes on distributions   4.83% 10.16% 6.88%
Class A | after taxes on distributions and sale of fund shares   8.04% 10.25% 7.03%
Class B before taxes 9.94% 13.56% 9.02%
Class C before taxes 13.46% 13.75% 8.85%
Class M before taxes 10.70% 13.24% 8.74%
Class R before taxes 14.95% 14.32% 9.40%
Class Y before taxes 15.55% 14.90% 9.95%
MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes)   19.80% 13.88% 8.94%
After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance reflects conversion to class A shares after eight years.

XML 10 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Label Element Value
Risk Return Abstract rr_RiskReturnAbstract  
Document Type dei_DocumentType 485BPOS
Document Period End Date dei_DocumentPeriodEndDate Dec. 31, 2017
Registrant Name dei_EntityRegistrantName PUTNAM GLOBAL HEALTH CARE FUND
Central Index Key dei_EntityCentralIndexKey 0000357295
Amendment Flag dei_AmendmentFlag false
Trading Symbol dei_TradingSymbol PHSTX
Document Creation Date dei_DocumentCreationDate Dec. 27, 2018
Document Effective Date dei_DocumentEffectiveDate Dec. 30, 2018
Prospectus Date rr_ProspectusDate Dec. 30, 2018
Putnam Global Health Care Fund  
Risk Return Abstract rr_RiskReturnAbstract  
Risk/Return [Heading] rr_RiskReturnHeading Fund Summary
Objective [Heading] rr_ObjectiveHeading Goal
Objective, Primary [Text Block] rr_ObjectivePrimaryTextBlock Putnam Global Health Care Fund seeks capital appreciation.
Expense [Heading] rr_ExpenseHeading Fees and expenses
Expense Narrative [Text Block] rr_ExpenseNarrativeTextBlock The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 50 of the fund's prospectus, in the Appendix to the fund's prospectus, and in How to buy shares beginning on page II-1 of the fund's statement of additional information (SAI).
Shareholder Fees Caption [Text] rr_ShareholderFeesCaption Shareholder fees (fees paid directly from your investment)
Operating Expenses Caption [Text] rr_OperatingExpensesCaption Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Portfolio Turnover [Heading] rr_PortfolioTurnoverHeading Portfolio turnover
Portfolio Turnover [Text Block] rr_PortfolioTurnoverTextBlock The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 49%.
Portfolio Turnover, Rate rr_PortfolioTurnoverRate 49.00%
Expense Breakpoint Discounts [Text] rr_ExpenseBreakpointDiscounts You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 50 of the fund's prospectus, in the Appendix to the fund's prospectus, and in How to buy shares beginning on page II-1 of the fund's statement of additional information (SAI).
Expense Breakpoint, Minimum Investment Required [Amount] rr_ExpenseBreakpointMinimumInvestmentRequiredAmount $ 50,000
Expense Example [Heading] rr_ExpenseExampleHeading Example
Expense Example Narrative [Text Block] rr_ExpenseExampleNarrativeTextBlock The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Strategy [Heading] rr_StrategyHeading Investments, risks, and performance Investments
Strategy Narrative [Text Block] rr_StrategyNarrativeTextBlock Investments
For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and
midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund’s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days’ notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.

The use of the term “global” in the fund’s name is meant to emphasize that we look for investment opportunities on a worldwide basis and that our investment strategies are not constrained by the countries or regions in which companies are located. Under normal market conditions, the fund intends to invest in at least five different countries and at least 40% of its net assets in securities of foreign companies (or, if less, at least the percentage of net assets that is 10% less than the percentage of the fund’s benchmark represented by foreign companies, as determined by the providers of the benchmark).
Risk [Heading] rr_RiskHeading Risks
Risk Narrative [Text Block] rr_RiskNarrativeTextBlock It is important to understand that you can lose money by investing in the fund.

The value of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in the financial markets, and factors related to a specific issuer or industry. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest a greater percentage of its assets in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation), and may be illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Risk Lose Money [Text] rr_RiskLoseMoney It is important to understand that you can lose money by investing in the fund.
Risk Nondiversified Status [Text] rr_RiskNondiversifiedStatus Our policy of concentrating on a limited group of industries and the fund's "non-diversified" status, which means the fund may invest a greater percentage of its assets in fewer issuers than a "diversified fund," can increase the fund's vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund.
Risk Not Insured Depository Institution [Text] rr_RiskNotInsuredDepositoryInstitution An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Bar Chart and Performance Table [Heading] rr_BarChartAndPerformanceTableHeading Performance
Performance Narrative [Text Block] rr_PerformanceNarrativeTextBlock The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Performance Information Illustrates Variability of Returns [Text] rr_PerformanceInformationIllustratesVariabilityOfReturns The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time.
Performance Availability Website Address [Text] rr_PerformanceAvailabilityWebSiteAddress putnam.com
Performance Past Does Not Indicate Future [Text] rr_PerformancePastDoesNotIndicateFuture Please remember that past performance is not necessarily an indication of future results.
Bar Chart [Heading] rr_BarChartHeading Annual total returns for class A shares before sales charges
Bar Chart Does Not Reflect Sales Loads [Text] rr_BarChartDoesNotReflectSalesLoads The bar chart does not reflect the impact of sales charges. If it did, performance would be lower.
Bar Chart Closing [Text Block] rr_BarChartClosingTextBlock Year-to-date performance
through 9/30/18    10.88%

Best calendar quarter
Q1 2013   13.14%

Worst calendar quarter
Q3 2011     −17.98%
Year to Date Return, Label rr_YearToDateReturnLabel Year-to-date performance through
Bar Chart, Year to Date Return, Date rr_BarChartYearToDateReturnDate Sep. 30, 2018
Bar Chart, Year to Date Return rr_BarChartYearToDateReturn 10.88%
Highest Quarterly Return, Label rr_HighestQuarterlyReturnLabel Best calendar quarter
Highest Quarterly Return, Date rr_BarChartHighestQuarterlyReturnDate Mar. 31, 2013
Highest Quarterly Return rr_BarChartHighestQuarterlyReturn 13.14%
Lowest Quarterly Return, Label rr_LowestQuarterlyReturnLabel Worst calendar quarter
Lowest Quarterly Return, Date rr_BarChartLowestQuarterlyReturnDate Sep. 30, 2011
Lowest Quarterly Return rr_BarChartLowestQuarterlyReturn (17.98%)
Performance Table Heading rr_PerformanceTableHeading Average annual total returns after sales charges (for periods ended 12/31/17)
Performance Table Uses Highest Federal Rate rr_PerformanceTableUsesHighestFederalRate After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.
Performance Table Not Relevant to Tax Deferred rr_PerformanceTableNotRelevantToTaxDeferred Actual after-tax returns depend on an investor's tax situation and may differ from those shown.
Performance Table One Class of after Tax Shown [Text] rr_PerformanceTableOneClassOfAfterTaxShown After-tax returns are shown for class A shares only and will vary for other classes.
Performance Table Closing [Text Block] rr_PerformanceTableClosingTextBlock After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance reflects conversion to class A shares after eight years.
Putnam Global Health Care Fund | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.75%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [1]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.25%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 1.08%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 679
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 899
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,136
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,816
Annual Return 2008 rr_AnnualReturn2008 (17.12%)
Annual Return 2009 rr_AnnualReturn2009 25.17%
Annual Return 2010 rr_AnnualReturn2010 2.06%
Annual Return 2011 rr_AnnualReturn2011 (1.41%)
Annual Return 2012 rr_AnnualReturn2012 21.98%
Annual Return 2013 rr_AnnualReturn2013 41.72%
Annual Return 2014 rr_AnnualReturn2014 27.47%
Annual Return 2015 rr_AnnualReturn2015 7.54%
Annual Return 2016 rr_AnnualReturn2016 (11.68%)
Annual Return 2017 rr_AnnualReturn2017 15.28%
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 8.65%
5 Years rr_AverageAnnualReturnYear05 13.26%
10 Years rr_AverageAnnualReturnYear10 9.03%
Putnam Global Health Care Fund | Class B  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 5.00% [2]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 1.83%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 686
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 876
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,190
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 1,951
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 186
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 576
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 990
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,951
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 9.94%
5 Years rr_AverageAnnualReturnYear05 13.56%
10 Years rr_AverageAnnualReturnYear10 9.02%
Putnam Global Health Care Fund | Class C  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [3]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 1.83%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 286
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 576
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 990
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 2,148
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 186
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 576
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 990
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,148
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 13.46%
5 Years rr_AverageAnnualReturnYear05 13.75%
10 Years rr_AverageAnnualReturnYear10 8.85%
Putnam Global Health Care Fund | Class M  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 3.50%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.75%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 1.58%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 505
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 831
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,180
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 2,163
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 10.70%
5 Years rr_AverageAnnualReturnYear05 13.24%
10 Years rr_AverageAnnualReturnYear10 8.74%
Putnam Global Health Care Fund | Class R  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.50%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 1.33%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 135
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 421
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 729
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,601
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 14.95%
5 Years rr_AverageAnnualReturnYear05 14.32%
10 Years rr_AverageAnnualReturnYear10 9.40%
Putnam Global Health Care Fund | Class Y  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Other expenses rr_OtherExpensesOverAssets 0.21%
Total annual fund operating expenses rr_ExpensesOverAssets 0.83%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 85
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 265
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 460
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,025
Label rr_AverageAnnualReturnLabel before taxes
1 Year rr_AverageAnnualReturnYear01 15.55%
5 Years rr_AverageAnnualReturnYear05 14.90%
10 Years rr_AverageAnnualReturnYear10 9.95%
Putnam Global Health Care Fund | after taxes on distributions | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 4.83%
5 Years rr_AverageAnnualReturnYear05 10.16%
10 Years rr_AverageAnnualReturnYear10 6.88%
Putnam Global Health Care Fund | after taxes on distributions and sale of fund shares | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 8.04%
5 Years rr_AverageAnnualReturnYear05 10.25%
10 Years rr_AverageAnnualReturnYear10 7.03%
Putnam Global Health Care Fund | MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes)  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 19.80%
5 Years rr_AverageAnnualReturnYear05 13.88%
10 Years rr_AverageAnnualReturnYear10 8.94%
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] This charge is phased out over six years.
[3] This charge is eliminated after one year.
XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 11 86 1 true 10 0 false 2 false true R1.htm 00000003 - Document - Putnam Global Health Care Fund Summary {Unlabeled} Sheet http://putnam.com/role/PutnamGlobalHealthCareFundSummaryUnlabeled Putnam Global Health Care Fund Summary 1 false false R8.htm 040000 - Disclosure - Risk/Return Detail Data {Elements} Sheet http://xbrl.sec.gov/rr/role/RiskReturnDetailData Risk/Return Detail Data 2 false false All Reports Book All Reports phstx-20181227.xml phstx-20181227.xsd phstx-20181227_def.xml phstx-20181227_lab.xml phstx-20181227_pre.xml BarChart1.png http://xbrl.sec.gov/dei/2012-01-31 http://xbrl.sec.gov/rr/2012-01-31 true false ZIP 16 0000928816-19-000075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000928816-19-000075-xbrl.zip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end